Comparative Pharmacology
Head-to-head clinical analysis: CROMOLYN SODIUM versus NASALCROM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CROMOLYN SODIUM versus NASALCROM.
CROMOLYN SODIUM vs NASALCROM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Stabilizes mast cell membranes, inhibiting release of histamine and other mediators of inflammation.
Cromolyn sodium stabilizes mast cells by inhibiting the release of histamine and other mediators of inflammation from sensitized mast cells. The exact molecular mechanism is not fully understood but may involve inhibition of calcium ion influx into mast cells.
For bronchial asthma: 20 mg (2 capsules) orally 4 times daily, administered 1 hour before meals and at bedtime. For allergic rhinitis: 1 spray (5.2 mg) in each nostril 3-6 times daily. For mastocytosis: 200 mg orally 4 times daily.
One spray (5.2 mg) into each nostril 3-4 times daily (maximum 6 times daily).
None Documented
None Documented
Terminal elimination half-life is approximately 1-1.5 hours for the absorbed fraction; the short half-life necessitates frequent dosing (e.g., 4 times daily) for sustained clinical effect.
Terminal elimination half-life is 1-2 hours; clinically, due to local mast cell stabilization, systemic levels do not correlate with effect.
Primarily excreted unchanged in bile and feces (approximately 98% after oral administration); renal excretion is minimal (<1% unchanged in urine). After inhalation, a small amount is absorbed systemically and similarly excreted via bile/feces.
Primarily unchanged drug; renal excretion accounts for ~90% of elimination, with minor biliary/fecal excretion (<5%).
Category A/B
Category C
Mast Cell Stabilizer
Mast Cell Stabilizer